Posology : מינונים

4.2. Posology and method of administration                            above.
Posology
Adult patients                                                     Method of administration For all adult indications except diabetic gastroparesis and        A minimum interval of 6 hours must be observed facilitation of diagnostic procedures (see below):                 between 2 doses, even in case of vomiting or rejection of
• The recommended dose is 10 mg, 1 to 3 times a day.               the dose (see section 4.4).
• The maximum recommended daily dose is 30 mg or 0.5               METOCLOPRAMIDE S.A.L.F 10mg/2ml can be mg/kg bodyweight whichever is lower.                               administered intravenously or intramuscularly.
The intravenous dose must be administered as a slow                The time interval of at least 6 hours specified in the bolus (over a duration of at least 3 minutes) in order to          section 4.2 should be respected between each reduce the risk of adverse effects (e.g., low blood                metoclopramide administration, even in case of pressure, akathisia). The duration of treatment by                 vomiting and rejection of the dose, in order to avoid injection must be as short as possible and treatment               overdose.
must be continued orally as soon as possible.
Prolonged treatment with metoclopramide may cause
Special populations                                                tardive dyskinesia, potentially irreversible, especially in Elderly                                                            the elderly. Treatment should not exceed 3 months In elderly patients a dose reduction should be considered,         because of the risk of tardive dyskinesia (see section based on renal and hepatic function and overall frailty.           4.8). Treatment must be discontinued if clinical signs of tardive dyskinesia appear.
Renal impairment
In patients with end stage renal disease (Creatinine clearance     Neuroleptic malignant syndrome has been reported ≤ 15 ml/min), the daily dose should be reduced by 75%. In          with metoclopramide in combination with neuroleptics patients with moderate to severe renal impairment (Creatinine      as well as with metoclopramide monotherapy (see clearance 15-60 ml/min), the dose should be reduced by 50%         section 4.8). Metoclopramide should be discontinued (see section 5.2).                                                 immediately in the event of symptoms of neuroleptic malignant syndrome and appropriate treatment should
Hepatic impairment                                                 be initiated.
In patients with severe hepatic impairment, the dose should be reduced by 50% (see section 5.2).                               Special care should be exercised in patients with underlying neurological conditions and in patients
Pediatric population                                               being treated with other centrally acting drugs (see Metoclopramide is contraindicated in children aged less than       sections 4.3 and 4.5).
1 year (see section 4.3).                                          Symptoms of Parkinson's disease may also be exacerbated by metoclopramide.